For Veterinarians — Equine Performance Labs

Science Driven Solutions in Equine Care Designed Around Long-Term Soundness

equicenta® CTM is a cryopreserved allogeneic equine umbilical cord connective tissue matrix designed for intra-articular and peri-articular use in horses — a cushioning, space-filling matrix that provides supplemental structural support to musculoskeletal tissue spaces.

Clinical Use & Dosing Overview

Space-filling connective tissue matrix

Intended as a space-filling connective tissue matrix for use within and around equine joints, tendons, and ligaments in a single equine occasion.

Route of administration

Intra-articular and peri-articular (including intralesional) injection only; not for intravenous use.

Recommended volume per site

1.5 mL per joint, tendon, or ligament, with dose adjusted based on joint or lesion size and clinician judgment.

Single-use only

Each vial is intended for one patient and one occasion. Do not reuse, re-sterilize, or refreeze once thawed.

Plan

Use as part of a multimodal plan that may include controlled exercise, rehabilitation, and other standard-of-care interventions.

IFU

Instructions for Use — full technical and safety information.
Request IFU

Injection & Rehab Considerations

Use standard aseptic preparation and injection technique; avoid excessive injection pressure.

Maintain the product in the frozen state until preparation for thawing. Once thawed, use immediately and do not refreeze.

Inspect the product prior to use and do not inject if the vial is damaged or contamination is observed.

Some horses may exhibit transient post-injection inflammation or local inflammatory signs; monitor and manage per standard clinical practice.

Implement a structured rest and rehabilitation plan tailored to the treated site, discipline, and performance goal, with clear owner instructions.

Traceability & Compliance

Track every unit, end-to-end. Tissue tracking is handled through our comprehensive vet portal, designed to give veterinary practices seamless documentation, easy updates, and full-cycle traceability — from receipt through administration and reporting. Access is provided to verified veterinary practices upon account setup.

Each vial carries a unique identifier to support end-to-end traceability.

The portal captures product name, lot number, expiry, patient ID, administration date, and tissue disposition (including discarded units).

Records are updated in real time and stored as a single source of truth, accessible to your clinical and administrative teams.

Audit-ready logs are retained in accordance with facility procedures and applicable regulations.

How Does It Work

Designed to support equine joints, tendons, and ligaments through a scaffold-based, biologically active approach.

Joint Treatment

Support joint health with a connective tissue matrix designed to complement your veterinarian’s treatment plan. equicenta® CTM provides a scaffold and bioactive signals within the joint environment, helping support comfort, function, and long-term soundness—without relying on steroids or repeated procedures.

See How It Works

Ligament Treatment

Target ligament injuries with a matrix-based approach that supports structured tissue response. equicenta® CTM delivers both biologic signaling and a native scaffold, designed to work alongside controlled rehabilitation to help support organized healing and reduce reliance on short-term symptom management.

See How It Works

Post-Surgical Treatment

Following surgery, the focus shifts to recovery, stability, and long-term outcome. equicenta® CTM can be used as part of a comprehensive post-operative plan to support the healing environment, complementing surgical repair and rehabilitation protocols while prioritizing the horse’s long-term function and comfort.

See How It Works

FAQ

Frequently asked questions, answered by our clinical team.

In what types of joint, tendon, or ligament cases is this product most appropriate?

equicenta® CTM is intended for equine musculoskeletal cases where connective tissue support is desirable, including lameness diagnosed as osteoarthritis, tendonitis, and desmitis. The application is best suited as a targeted approach in joints, tendons, and ligaments when your clinical exam and imaging identify an underlying abnormality, such as osteochondrosis or osteoarthritis, or a structural tear in tendon or ligament.

How should I select dose and volume for large vs. small joints or local lesions?

Our clinical study used a single dose per joint. Large joints, like the stifle joint received a single dose for each stifle pouch (medial, lateral and femorpatellar). Our results show it is effective at a single dose.* Our reference volume is 1.5 mL per site.

Can I administer this product with other intra-articular treatments, or should they be staged?

One advantage of equicenta is that a single dose has a duration of effect as long as 3 months in most conditions and performance improvements that are realized by 6 months based on our clinical data.* There should be no need for any other intra-articular treatment. If at 3 months there is no ultrasonographic or lameness improvement or they have regressed, then a second equicenta injection would be recommended. Staging is generally the more conservative approach. Separating treatments can make it easier to assess response and helps guide clear clinical decision-making for combined or sequential protocols.

What post-injection responses are typical, and when should I suspect infection or an adverse reaction?

Any injection will induce mild inflammation and for equicenta would typically go unnoticed by the owner as the horse is rested in the stall for a few days after the injection. Our studies have shown less than a handful of cases out of hundreds in which soreness or warmth was noticed at the injection site.* However, as with any injection a mild transient soreness, stiffness, or localized inflammation may occur after injection. Persistent, worsening, or severe pain, swelling, heat, lameness, or systemic illness should prompt evaluation for infection or an adverse response.

What are the key storage, thawing, and handling steps to maintain product integrity?

Store frozen at ultra-low temperature according to the product instructions. Thaw just prior to use, keep the vial closed during thawing, gently mix to resuspend contents, and administer using aseptic technique; do not refreeze once thawed.

What are my responsibilities for tissue tracking and record-keeping for this allogeneic tissue?

Tissue tracking is managed through our comprehensive vet portal. For each unit used, log patient identification, treatment site, date of administration, and treating veterinarian directly in the portal. The portal maintains audit-ready records; follow your facility’s procedures for any additional retention requirements.

* Data on file.

Real horses. Real decisions.

“
In cases like severe synovitis and collateral ligament injury, equicenta® CTM produced faster, more complete responses than I typically see with other treatments.
Dr. Lacher Read More

“
Before the ribbons, before the results — Vivi’s journey through injury, recovery, and return to work.
Vivi’s Story Read More

“
After tearing the tendon in his front leg, we weren’t sure who Moo would be on the other side—but with equicenta® CTM, we got him back.
Teri T. Read More

Science Driven Solutions in Equine Care Designed Around Long-Term Soundness

The science behind equicenta® CTM

The Biologic Breakdown: In Vitro Characterization of Equine UC Allograft

Paving the Way: Defining Safety, Consistency & Clinical Readiness in Equine Biologics

The Safety Standard: Evaluating Cryopreserved Equine UC Allografts

The Consistency Code: Evaluating Protein & Cytokine Uniformity in Equine UC Allografts